Firefly Neuroscience (NASDAQ: AIFF) has announced a partnership with the Department of War (DoW) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from post-traumatic stress disorder (PTSD) and/or traumatic brain injury (TBI).
Firefly states that this public-private brain health partnership originated from early work by closely held Evoke Neuroscience (acquired by Firefly in May 2025) in collaboration with the U.S. Naval Medical Center Camp Lejeune Family Medicine Residency program. Further details remain confidential pursuant to applicable agreements.
In a statement, Dave DeCaprio, president and COO of Firefly, commented, “Every U.S. service member who comes home carrying the invisible wounds of PTSD and/or TBI deserves to be truly seen — not just screened. This partnership reflects our core mission: to bring the most advanced, objective brain health tools to the people who need them most, so that military healthcare providers may act earlier, treat more precisely, and give people a real path forward. We are proud that Firefly’s technology is being trusted to serve those who have sacrificed so much for this country.”
Greg Lipschitz, CEO of Firefly, remarked, “We believe that this ongoing strategic partnership positions us well to benefit from the significant and growing U.S. government investment in military brain health—with a validated, FDA-cleared platform. Our work with U.S. service members also complements our strategic initiative to build a proprietary foundation model of the human brain by combining a rapidly growing repository of brain scan data and important access to NVIDIA GPU acceleration to power next-generation EEG/ERP processing.”
Firefly’s FDA 510(k)-cleared, AI-powered EEG/ERP platform is being utilized across related DoW programs, providing military healthcare providers with objective, quantitative neurological data intended to support more precise diagnosis, individualized treatment planning, and measurable outcomes tracking. The platform is non-invasive, scalable across both clinical and operational environments, and designed for real-world deployment at scale. The DoW partnership represents a potentially significant channel for Firefly’s commercial strategy, expanding the company’s footprint into the U.S. government and defense health sectors.
